Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence

Purpose: In this prospective survey of referring physicians, we investigated whether and how Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA-11 PET/CT) affects the actually implemented management of prostate cancer patients wih biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median Prostate Specific Antigen (PSA) value 1.7 ng/ml (range 0.05-202)). Referring physicians completed one questionnaire prior to the scan to indicate the treatment plan without PSMA-11 PET/CT information (Q1; n = 101); one immediately after the scan to denote intended management changes (Q2; n = 101); and one 3 to 6 months later to document the final implemented management (Q3; n = 56). Implemented management was also obtained via electronic chart review and/or patient contact (n = 45). Results: Complete documented management strategy (Q1+Q2+implemented management) was available in 101/161 patients (63%). Seventy-six of these (75%) had a positive PSMA-11 PET/CT study. The actually implemented management differed from the pre-scan intended treatment plan (Q1) in 54/101 patients (53%). The post-scan intended management (Q2) differed from the pre-scan intended management (Q1) in 62/101 patients (61%); however, these intended changes were not implemented in 29/62 patients (47%). Pelvic nodal and extra-pelvic metastatic disease on PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) were significantly associated with implemented management changes (P = 0,001, 0.05). Conclusion: PSMA-11 PET/CT results in actually implemented management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after PSMA-11 PET/CT frequently differ from actually implemented management changes.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Dec 14 [Epub ahead of print]

Jérémie Calais, Wolfgang P Fendler, Matthias Eiber, Jeannine Gartmann, Fang-I Chu, Nicholas G Nickols, Robert R Reiter, Matthew B Rettig, Leonard S Marks, Thomas E Ahlering, Lynda Huynh, Roger Slavik, Pawan Gupta, Andrew Quon, Martin S Allen-Auerbach, Johannes Czernin, Ken Herrmann

UCLA, France., UC Irvine.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.